Biogen   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Geneva Switzerland (1978)
Status: Acquired by Biogen-IDEC (2003)

Organization Overview

First Clinical Trial
1995
NCT00168740
First Marketed Drug
1996
interferon beta-1a (Avonex)
First NDA Approval
1996
interferon beta-1a (Avonex)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Biogen | BIOGEN | Biogen Inc. | BIOGEN INC | BIOGEN MA | Biogen MA Inc. | Bioverativ (Biogen)